New Guidelines Warn Against Calcium Channel Blockers in Certain Patients

OCTOBER 01, 2004

Recent guidelines from the New American College of Chest Physicians alert practitioners to the potentially fatal effects of prescribing calcium channel blockers for patients with unstable pulmonary arterial hypertension (PAH). While those drugs are commonly used for treating high blood pressure, these new, evidence-based guidelines warn against empiric use in patients unresponsive to acute pulmonary vasodilator testing due to an increased risk of adverse and possibly fatal side effects. Members of the expert panel who determined these new guidelines recommend that physicians conduct genetic testing on patients who have a family history of PAH, as well as advance screening for patients with chronic diseases that may predispose them to PAH. (The findings were reported in Chest, July 2004.)



SHARE THIS SHARE THIS
0

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.